These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35631439)

  • 1. Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction.
    Patil SP; Fattakhova E; Hofer J; Oravic M; Bender A; Brearey J; Parker D; Radnoff M; Smith Z
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
    Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
    Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based virtual screening for PDL1 dimerizers: Evaluating generic scoring functions.
    Tran-Nguyen VK; Simeon S; Junaid M; Ballester PJ
    Curr Res Struct Biol; 2022; 4():206-210. PubMed ID: 35769111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
    Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
    Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers.
    Gómez-Sacristán P; Simeon S; Tran-Nguyen VK; Patil S; Ballester PJ
    J Adv Res; 2025 Jan; 67():185-196. PubMed ID: 38280715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
    Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
    Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using phage-assisted continuous evolution (PACE) to evolve human PD1.
    Ye X; Tu M; Piao M; Yang L; Zhou Z; Li Z; Lin M; Yang Z; Zuo Z
    Exp Cell Res; 2020 Nov; 396(1):112244. PubMed ID: 32860814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy.
    Luo K; Liu S; Shen X; Xu J; Shi C; Chao Y; Wen Z; Zhang K; Wang R; Liu B; Jiang Y
    Front Cell Dev Biol; 2022; 10():1003656. PubMed ID: 36467413
    [No Abstract]   [Full Text] [Related]  

  • 10. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
    Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
    Front Immunol; 2022; 13():862084. PubMed ID: 35493449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
    Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
    Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors.
    Wu Y; Lin L; Liu X
    Dis Markers; 2020; 2020():7291586. PubMed ID: 32587640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
    Guo L; Bodo J; Durkin L; Hsi ED
    Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
    Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of PDL1/L2 by different induced-fit mechanisms of PD1: a comparative study of molecular dynamics simulations.
    Lyu N; Wang K; Zhang F; Qin H; Zhao Y; Wu R; Si Y; Wang L
    Phys Chem Chem Phys; 2020 Jan; 22(3):1276-1287. PubMed ID: 31850422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Profiling Reveals Immune-Related Gene Differences in Lung Cancer Patients Stratified by PD1/PDL1 Expression: Implications for Immunotherapy Efficacy.
    Ye Z; Huang T; Hu K; Zhou H; Huang L; Wang L
    J Appl Genet; 2024 Feb; ():. PubMed ID: 38363451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting a Stable Dimeric Form of the PD1-PDL1 Complex: Implications for Understanding the PD1 Activation Mechanism.
    Ponce LF; Ramírez-Echemendia DP; León K; Valiente PA
    J Phys Chem B; 2023 Jul; 127(26):5764-5771. PubMed ID: 37343227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
    Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
    Front Oncol; 2022; 12():732814. PubMed ID: 35280727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.
    Xing X; Guo J; Ding G; Li B; Dong B; Feng Q; Li S; Zhang J; Ying X; Cheng X; Guo T; Du H; Hu Y; Zhou T; Wang X; Li L; Li Q; Xie M; Li L; Gao X; Shan F; Li Z; Jia S; Wen X; Wang J; Ji J
    Oncoimmunology; 2018; 7(3):e1356144. PubMed ID: 29399387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
    Stenehjem DD; Tran D; Nkrumah MA; Gupta S
    Onco Targets Ther; 2018; 11():5973-5989. PubMed ID: 30275703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.